Palvella Therapeutics (PVLA) Income from Continuing Operations (2013 - 2026)
Palvella Therapeutics' (PVLA) quarterly Income from Continuing Operations came in at 15767000.0 in Q1 2026, down 92.63% year-on-year from 214018067.99 in Q1 2025, and down 23.39% on a QoQ basis from 12778000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Income from Continuing Operations data on file, last reported at 15767000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 92.63% year-over-year to 15767000.0 in Q1 2026; TTM through Mar 2026 was 49361000.0, a 113.84% decrease from a year earlier, with the FY2025 full-year figure at 41779000.0, down 139.64% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 15767000.0, down from 12778000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PVLA reached as high as 14986000.0 in Q4 2023 and fell as low as 16011000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 7807235.29 across 5 years, with a median of 9471000.0 in 2025.
- Across the five-year window, Income from Continuing Operations jumped 221.65% in 2023 and tumbled 366.92% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 12319000.0 in 2022, then soared by 221.65% to 14986000.0 in 2023, then plunged by 126.36% to 3951000.0 in 2024, then tumbled by 223.41% to 12778000.0 in 2025, then decreased by 23.39% to 15767000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 15767000.0 in Q1 2026, 12778000.0 in Q4 2025, and 11345000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - | -15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | -12.78 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -3.95 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | 14.99 Mn |
| Sep 30, 2023 | -12.31 Mn |
| Jun 30, 2023 | 1.56 Mn |
| Mar 31, 2023 | -16.01 Mn |
| Dec 31, 2022 | -12.32 Mn |
| Sep 30, 2022 | -12.67 Mn |
| Jun 30, 2022 | -12.93 Mn |
| Mar 31, 2022 | -8.06 Mn |
| Dec 31, 2021 | -11.70 Mn |
| Sep 30, 2021 | -19.61 Mn |
| Jun 30, 2021 | -17.36 Mn |